-
Article
Monoclonal antibody therapy in multiple myeloma
The therapeutic landscape of multiple myeloma (MM) has evolved spectacularly over the past decade with the discovery and validation of proteasome inhibitors and immunomodulatory agents as highly active agents,...
-
Article
Erratum: Polymorphisms in xenobiotic transporters ABCB1, ABCG2, ABCC2, ABCC1, ABCC3 and multiple myeloma risk: a case—control study in the context of the International Multiple Myeloma rESEarch (IMMEnSE) consortium
Correction to: Leukemia (2012) 26, 1419–1422; doi:10.1038/leu.2011.352 Since the publication of this article the authors have noticed errors within the original text of the manuscript. Allele nomenclature of s...
-
Article
Polymorphisms in xenobiotic transporters ABCB1, ABCG2, ABCC2, ABCC1, ABCC3 and multiple myeloma risk: a case–control study in the context of the International Multiple Myeloma rESEarch (IMMEnSE) consortium
-
Article
Genetic polymorphisms associated with outcome in multiple myeloma patients receiving high-dose melphalan
High-dose melphalan (HDM) is an essential component in the treatment of patients with multiple myeloma (MM). Few data are available regarding genetic polymorphisms associated with patient outcome or toxicity i...
-
Article
A20/TNFAIP3, a new estrogen-regulated gene that confers tamoxifen resistance in breast cancer cells
The zinc-finger protein A20/TNFAIP3, an inhibitor of nuclear factor-κB (NF-κB) activation, has been shown to protect MCF-7 breast carcinoma cells from TNFα-induced apoptosis. As estrogen receptor (ER) status is a...
-
Article
Rituximab in CD20 positive multiple myeloma
-
Article
Autoimmune thrombocytopenic purpura after autologous stem cell transplantation
The pathogenesis of thrombocytopenia occurring after autologous stem cell transplantation (ASCT) remains unclear. Six cases of classical peripheral thrombocytopenia that developed after ASCT for non-Hodgkin's ...
-
Article
Amifostine reduces mucosal damage after high-dose melphalan conditioning and autologous peripheral blood progenitor cell transplantation for patients with multiple myeloma
High-dose melphalan (HDM) has been adopted as standard therapy in the treatment of multiple myeloma. This treatment is associated with non-selective cytotoxicity, causing oral mucositis as the major non-hemato...
-
Article
Identification and validation of seven genes, as potential markers, for the differential diagnosis of small B cell lymphomas (small lymphocytic lymphoma, marginal zone B cell lymphoma and mantle cell lymphoma) by cDNA macroarrays analysis
-
Article
Epileptic seizures after autologous peripheral blood progenitor infusion in a patient treated with high-dose chemotherapy for myeloma
Bone Marrow Transplantation (2002) 29, 544. doi:10.1038/sj.bmt.1703383
-
Article
Nucleoside analogues: mechanisms of drug resistance and reversal strategies
Nucleoside analogues (NA) are essential components of AML induction therapy (cytosine arabinoside), effective treatments of lymphoproliferative disorders (fludarabine, cladribine) and are also used in the trea...
-
Article
Late autologous transplantation in chronic myelogenous leukemia with peripheral blood progenitor cells mobilized by G-CSF and interferon-α
In chronic myelogenous leukemia (CML), autologous stem cell transplantation could be a promising new approach for patients with no cytogenetic response after interferon α (IFN-α) therapy. We report data on 28 ...
-
Article
A prospective study of intensive induction therapy with high-dose consolidation in patients with aggressive non-Hodgkin's lymphoma and two or three adverse prognostic factors
Patients with nhl and two or three factors of the international prognostic index (ipi) have a poor prognosis. we performed a prospective trial of intensive induction therapy followed with high-dose consolidati...
-
Article
Toxicities after peripheral blood progenitor cell transplantation for lymphoid malignancies: analysis of 300 cases in a single institution
Two hundred and seventy-seven consecutive patients with non-Hodgkin’s lymphoma (n = 207), Hodgkin’s disease (n = 27) and multiple myeloma (n = 43) were intensified from October 1989 until April 1997 and received ...
-
Article
Profiles and prognostic values of LDH isoenzymes in patients with non-Hodgkin’s lymphoma
Serum lactic dehydrogenase (LDH) is an important prognostic factor in patients with non-Hodgkin’s lymphoma (NHL). We have examined the LDH isoenzyme content in serum and CSF of patients with NHL, at diagnosis ...
-
Article
Mantle cell lymphoma: a retrospective study of 121 cases
Mantle cell lymphoma (MCL) patients represent a difficult problem, sometimes to establish the diagnosis but mostly because of their refractoriness to standard lymphoma treatments. Which treatments to apply and...
-
Article
Reduced progression-free survival in elderly patients receiving intensification with autologous peripheral blood stem cell reinfusion for multiple myeloma
Between 1990 and 1997, 55 patients with high risk multiple myeloma underwent high-dose therapy with peripheral blood stem cell transplantation. Intensification consisted of high-dose L-PAM in 54 patients, and ...